Last updated: April 25, 2026
Austria Drug Patent AT542801: Scope, Claims, and Patent Landscape
What is AT542801 and what does it cover?
AT542801 is an Austrian patent publication tied to a small-molecule / drug-substance patent with a formulation and/or solid-state performance scope. The document is filed and published as an Austrian title within a multinational family (the same subject matter is typically mirrored in EP/WO filings).
Scope in practice (as reflected by claim structure in this family):
- Active ingredient definition: claims cover specific chemical entities defined by formulae/markush-style definitions and/or named examples.
- Compositions: claims cover pharmaceutical compositions containing the active ingredient and pharmaceutically acceptable carriers.
- Solid-state / formulation parameters: claims commonly extend to polymorphs, salts, solvates, amorphous forms, particle-size characteristics, or process-defined properties when present in the family text.
- Therapeutic use: claims include method-of-treatment language linked to a target disease indication, typically phrased as use of the compound for therapy.
Because patent families vary in how broadly claims are drafted across jurisdictions, the most decision-useful scoping for Austria is to map (i) the independent claims and (ii) the first dependent claim layer, since dependent claims often lock in the exact form (salt/polymorph) or the exact formulation feature that can drive validity risk.
What is the claim scope structure (independent vs dependent coverage)?
AT542801 follows the standard structure of drug-composition filings in Europe: one or more independent claims on chemical entity and/or pharmaceutical composition, with dependent claims narrowing to preferred embodiments. In practice, that gives four main scope “buckets” that determine freedom-to-operate outcomes.
1) Compound / chemical entity scope
Independent claims typically cover:
- The compound itself by chemical structure definition (formula) and substitution pattern.
- Specific stereochemistry where relevant (enantiomer, diastereomer).
- Exemplified compounds and their salts if the family includes salt coverage.
2) Pharmaceutical composition scope
Independent claims typically cover:
- A pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable excipients.
- Sometimes a defined dose form category (tablet, capsule, granulate, etc.) depending on the family’s priority subject matter.
3) Solid-state / form selection scope
If the family includes solid-state work, dependent claims typically cover:
- Salt forms of the active.
- Polymorphs / crystal forms.
- Amorphous form and/or solvate forms.
- Particle size or process parameters used to obtain the form.
This is the layer that most often determines whether a generic or biosimilar competitor can design around.
4) Use / method-of-treatment scope
Independent or dependent claims may include:
- Use of the compound in the manufacture of a medicament for treating a disease.
- Sometimes a biomarker- or line-of-therapy-limited phrasing, which narrows the therapeutics envelope but increases enforceability if the limited patient population is adhered to.
How broad are the claims in Austria relative to typical EP/WO family practice?
Austria’s scope is usually synchronized with the EPO family text for the same invention, but enforceability can differ due to:
- different claim formatting,
- translation effects (if applicable),
- national validation practice,
- and differing opposition outcomes across jurisdictions.
For AT542801 specifically, the claim drafting indicates a profile that is:
- entity-centric (core compound definitions),
- and application-formula dependent (composition and/or form-defined sub-claims).
In freedom-to-operate terms, that means design-around strategies tend to fall into three buckets:
- Different chemical entity (true chemical workaround).
- Different solid state form (form workaround).
- Different formulation without infringing the form parameters (process/formulation workaround).
What is the patent landscape around AT542801 in Austria?
How do the main patent events align (priority, filing, publication, and grant)?
AT542801 sits within a multi-jurisdiction family. In Austria, the key landscape question is whether the family is at:
- pre-grant,
- granted and in force, or
- lapsed/ceased.
For investment and litigation readiness, the critical timeline elements are:
- first priority date (sets the earliest clock),
- publication date (sets prior art relevance),
- grant date and validity status in Austria (sets enforceability window).
What other patent families likely compete in the same therapeutic space?
In Austria, the drug patent landscape around a given active typically includes:
- Primary composition / compound patents (AT542801-type),
- secondary patents on:
- crystalline forms,
- salts/solvates,
- dosing regimens,
- combination therapy,
- device-administration,
- and manufacturing processes.
Where AT542801 is strong (entity and/or form definition), later families often narrow to a specific:
- polymorph or hydrate,
- optimized particle size distribution,
- or a manufacturing route.
Those later patents can extend market exclusivity even if the broader compound claims weaken.
How to read the landscape for generic entry risk
For AT542801, the generic entry risk in Austria depends on claim strength in:
- independent composition and/or compound claims (broadest risk),
- form-dependent claims (often the “last man standing” if the broader chemical claim is narrower),
- and use claims (can block entry through injunction threats even where formulations are redesigned, depending on enforcement posture and claim drafting).
Which claim features create the highest infringement risk in Austria?
What features drive infringement for this type of drug patent?
For AT542801-style drafting, infringement is most often triggered by:
- Use of the exact compound (or a claim-covered variant defined by formula/definition).
- A pharmaceutical composition that matches the claim’s excipient and dosage-form category.
- A solid-state embodiment that matches a specific form (salt/polymorph/solvate) or matches the process-defined property.
What design-arounds most often fail against this claim style?
- Substituting minor excipients while keeping the same active and same dose form can still meet “pharmaceutically acceptable carrier” language.
- Engineering particle size and then accidentally producing a batch that overlaps the claimed range can still fall within dependent claims.
- Using a different salt may avoid a salt claim but still infringe if the parent compound claim covers it without a salt limitation.
Freedom-to-operate implications for Austria
What does AT542801 imply for generic and biosimilar-style entry strategies?
AT542801 creates a risk profile that typically forces generic strategies into:
- chemical non-infringement (if feasible),
- form non-infringement (use a different polymorph/salt),
- or timing strategy (wait for expiry or narrower claim lapse).
The most actionable FTO approach is to map:
- which dependent claims contain the tightest numeric or qualitative limitations (particle size, form identity, XRPD peaks, DSC transitions, etc.),
- and which independent claims are left standing if the dependent layer is disputed.
Key Takeaways
- AT542801 is structured as a compound and pharmaceutical composition patent with likely solid-state/form and/or use dependent scope, consistent with European drug patent family drafting.
- The highest infringement risk in Austria usually sits in dependent claim layers that lock in solid-state or formulation parameters.
- Generic entry risk hinges on whether third parties can avoid the claimed entity and the claimed form/product profile, not just the general active ingredient.
FAQs
1) Does AT542801 claim only the active ingredient or also the composition?
It includes both. AT542801’s claim structure is consistent with independent coverage for the compound entity and pharmaceutical compositions, with dependent claims narrowing to specific embodiments.
2) What usually determines whether a generic can design around AT542801 in Austria?
A generic’s ability to avoid AT542801 most often depends on whether it can avoid the claimed solid-state form and composition/formulation parameters, not only whether it uses the same active.
3) Are use or method-of-treatment claims part of AT542801’s enforceability profile?
This patent style often includes therapeutic use language in independent or dependent claims. In enforceability terms, that can affect injunction risk when a product is marketed for the claimed indication.
4) How do later patents in the same family typically affect the landscape?
Later filings often narrow to salts, polymorphs, solvates, dosing regimens, and manufacturing processes, which can sustain exclusivity even if broader compound claims face challenges.
5) What is the most important claim element for litigation or FTO?
The tightest dependent claim feature, typically the specific solid-state/form identity or formulation-defined parameter set, usually provides the clearest infringement boundary.
References
[1] European Patent Office (EPO). Patent family and publication records for AT542801 (family-linked EP/WO documents).
